Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immunotech Biopharm Ltd ( (HK:6978) ) has shared an update.
Immunotech Biopharm Ltd has announced a proposed rights issue to raise up to HK$307.84 million through the issuance of up to 123,135,430 Rights Shares. The rights issue is underwritten on a best-effort basis by Maxa Asset Management Limited and will proceed regardless of the subscription level, with any unsubscribed shares not being issued. This move is part of the company’s strategy to strengthen its financial position without requiring shareholder approval, as it complies with the relevant listing rules.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company is listed on the Hong Kong Stock Exchange and is involved in the biotechnology sector.
Average Trading Volume: 1,028,799
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.45B
See more data about 6978 stock on TipRanks’ Stock Analysis page.